Cargando…

Critical Needs in Advancing Shigella Vaccines for Global Health

Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.

Detalles Bibliográficos
Autores principales:	MacLennan, Calman A, Talaat, Kawsar R, Kaminski, Robert W, Cohen, Dani, Riddle, Mark S, Giersing, Birgitte K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071279/ https://www.ncbi.nlm.nih.gov/pubmed/34558631 http://dx.doi.org/10.1093/infdis/jiab462

Ejemplares similares

Frontiers in Shigella Vaccine Development
por: MacLennan, Calman Alexander, et al.
Publicado: (2022)

Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries
por: Giersing, Birgitte K, et al.
Publicado: (2023)

Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints
por: MacLennan, Calman A, et al.
Publicado: (2019)

The Shigella Vaccines Pipeline
por: MacLennan, Calman Alexander, et al.
Publicado: (2022)

Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies
por: Talaat, Kawsar R, et al.
Publicado: (2019)

Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group
por: Pavlinac, Patricia B., et al.
Publicado: (2022)

Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays
por: Kaminski, Robert W, et al.
Publicado: (2019)

Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data
por: Cohen, Dani, et al.
Publicado: (2023)

Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview
por: MacLennan, Calman A, et al.
Publicado: (2019)

What Drives the Value of a Shigella Vaccine?
por: Hausdorff, William P., et al.
Publicado: (2022)

Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy
por: Hosangadi, Divya, et al.
Publicado: (2019)

Consequences of Shigella infection in young children: a systematic review
por: Libby, Tanya E., et al.
Publicado: (2023)

Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei
por: Clarkson, Kristen A., et al.
Publicado: (2021)

Impact and Control of Sugar Size in Glycoconjugate Vaccines
por: Stefanetti, Giuseppe, et al.
Publicado: (2022)

Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines
por: Micoli, Francesca, et al.
Publicado: (2023)

Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019
por: Gottlieb, Sami L., et al.
Publicado: (2020)

Editorial Commentary: Out of Africa: Links Between Invasive Nontyphoidal Salmonella Disease, Typhoid Fever, and Malaria
por: MacLennan, Calman A.
Publicado: (2014)

Antibodies and Protection Against Invasive Salmonella Disease
por: MacLennan, Calman A.
Publicado: (2014)

An O Antigen Capsule Modulates Bacterial Pathogenesis in Shigella sonnei
por: Caboni, Mariaelena, et al.
Publicado: (2015)

Vaccines against invasive Salmonella disease: Current status and future directions
por: MacLennan, Calman A, et al.
Publicado: (2014)

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
por: Talaat, Kawsar R., et al.
Publicado: (2021)

Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
por: Clarkson, Kristen A., et al.
Publicado: (2021)

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score
por: Porter, Chad K., et al.
Publicado: (2018)

How Do We Meet the Supportive Care and Information Needs of Those Living With and Beyond Bladder Cancer?
por: MacLennan, Sara Jane, et al.
Publicado: (2020)

Salmonella Combination Vaccines: Moving Beyond Typhoid
por: MacLennan, Calman A, et al.
Publicado: (2023)

A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy
por: Kristensen, Debra, et al.
Publicado: (2021)

Immune responses to Neisseria gonorrhoeae and implications for vaccine development
por: Belcher, Thomas, et al.
Publicado: (2023)

COVID-19 and the Need for Global Critical Care Training. Why Ventilators Alone Are Not the Answer
por: Brotherton, B. Jason, et al.
Publicado: (2020)

Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009
por: Ispasanie, Emma, et al.
Publicado: (2014)

Leukocyte counts and lymphocyte subsets in relation to pregnancy and HIV infection in Malawian women
por: Mandala, Wilson L., et al.
Publicado: (2017)

Age- and sex-related changes in hematological parameters in healthy Malawians
por: Mandala, Wilson L, et al.
Publicado: (2017)

Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease
por: Lanzilao, Luisa, et al.
Publicado: (2015)

Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016
por: Khalil, Ibrahim A, et al.
Publicado: (2018)

A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014)
por: Uche, Ifeanyi Valentine, et al.
Publicado: (2017)

Modulation of Endotoxicity of Shigella Generalized Modules for Membrane Antigens (GMMA) by Genetic Lipid A Modifications: RELATIVE ACTIVATION OF TLR4 AND TLR2 PATHWAYS IN DIFFERENT MUTANTS
por: Rossi, Omar, et al.
Publicado: (2014)

Advanced human mucosal tissue models are needed to improve preclinical testing of vaccines
por: Kessie, David Komla, et al.
Publicado: (2021)

The need for core outcome sets in urological cancer research
por: MacLennan, Steven, et al.
Publicado: (2021)

Monoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella
por: Goh, Yun Shan, et al.
Publicado: (2015)

Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa
por: Mandala, Wilson L., et al.
Publicado: (2010)

Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed
por: Figueroa, J Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ujo0d483eg99dhaq35pmbamlsb